CN101273987A - 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 - Google Patents

取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 Download PDF

Info

Publication number
CN101273987A
CN101273987A CNA2008100965659A CN200810096565A CN101273987A CN 101273987 A CN101273987 A CN 101273987A CN A2008100965659 A CNA2008100965659 A CN A2008100965659A CN 200810096565 A CN200810096565 A CN 200810096565A CN 101273987 A CN101273987 A CN 101273987A
Authority
CN
China
Prior art keywords
chemical compound
inhibitor
formula
hyperlipemia
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008100965659A
Other languages
English (en)
Chinese (zh)
Inventor
D·G·霍姆斯
T·E·休斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101273987A publication Critical patent/CN101273987A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2008100965659A 2002-06-03 2003-06-02 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 Pending CN101273987A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38522002P 2002-06-03 2002-06-03
US60/385,220 2002-06-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB038128446A Division CN100402026C (zh) 2002-06-03 2003-06-02 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途

Publications (1)

Publication Number Publication Date
CN101273987A true CN101273987A (zh) 2008-10-01

Family

ID=29712145

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008100965659A Pending CN101273987A (zh) 2002-06-03 2003-06-02 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
CNB038128446A Expired - Fee Related CN100402026C (zh) 2002-06-03 2003-06-02 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB038128446A Expired - Fee Related CN100402026C (zh) 2002-06-03 2003-06-02 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途

Country Status (26)

Country Link
US (2) US20050176806A1 (ja)
EP (1) EP1513519B1 (ja)
JP (2) JP2005532338A (ja)
KR (1) KR20050012771A (ja)
CN (2) CN101273987A (ja)
AT (1) ATE422884T1 (ja)
AU (2) AU2003245903B2 (ja)
BR (1) BR0311535A (ja)
CA (1) CA2487297C (ja)
CY (1) CY1112800T1 (ja)
DE (1) DE60326232D1 (ja)
DK (1) DK1513519T3 (ja)
EC (1) ECSP045469A (ja)
ES (1) ES2321600T3 (ja)
HK (1) HK1074794A1 (ja)
IL (1) IL165181A (ja)
MX (1) MXPA04012149A (ja)
NO (1) NO333585B1 (ja)
NZ (1) NZ536832A (ja)
PL (1) PL210408B1 (ja)
PT (1) PT1513519E (ja)
RU (1) RU2362555C2 (ja)
SG (1) SG154333A1 (ja)
SI (1) SI1513519T1 (ja)
WO (1) WO2003101448A1 (ja)
ZA (1) ZA200409136B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245903B2 (en) * 2002-06-03 2006-11-30 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
ES2332920T3 (es) 2004-01-20 2010-02-15 Novartis Ag Proceso y formulacion de compresion directa.
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2114154B1 (en) * 2007-02-08 2013-08-28 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
WO2020197967A1 (en) * 2019-03-22 2020-10-01 Rush University Medical Center Combination of nasal gene delivery and oral cinnamic acid, oleamide or gemfibrozil for lysosomal stoarge disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP2823812A1 (en) * 1998-02-02 2015-01-14 Trustees Of Tufts College Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
EP1125922A1 (en) * 1998-11-02 2001-08-22 Welfide Corporation Pyrrolidine compounds and medicinal utilization thereof
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
JP4232332B2 (ja) * 1999-11-10 2009-03-04 末藏 岩田 タンク付電動床磨機用ブラシ台
CN1977842A (zh) * 2000-01-21 2007-06-13 诺瓦提斯公司 含有二肽基肽酶－iv抑制剂和抗糖尿病药物的联合形式
CA2464995A1 (en) * 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
PE20040291A1 (es) * 2002-03-22 2004-07-02 Novartis Ag COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
AU2003245903B2 (en) * 2002-06-03 2006-11-30 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
AU2006292377B2 (en) * 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events

Also Published As

Publication number Publication date
RU2362555C2 (ru) 2009-07-27
DK1513519T3 (da) 2009-06-02
KR20050012771A (ko) 2005-02-02
ZA200409136B (en) 2005-07-27
AU2003245903B2 (en) 2006-11-30
PT1513519E (pt) 2009-05-06
PL210408B1 (pl) 2012-01-31
CA2487297C (en) 2011-08-09
PL374016A1 (en) 2005-09-19
AU2003245903A1 (en) 2003-12-19
CN1658867A (zh) 2005-08-24
SG154333A1 (en) 2009-08-28
ATE422884T1 (de) 2009-03-15
IL165181A (en) 2010-06-16
JP2010155866A (ja) 2010-07-15
AU2006246483B9 (en) 2010-08-12
JP2005532338A (ja) 2005-10-27
DE60326232D1 (de) 2009-04-02
US20120014907A1 (en) 2012-01-19
WO2003101448A1 (en) 2003-12-11
MXPA04012149A (es) 2005-04-19
CA2487297A1 (en) 2003-12-11
EP1513519A1 (en) 2005-03-16
BR0311535A (pt) 2005-02-22
RU2004139029A (ru) 2005-08-27
SI1513519T1 (sl) 2009-06-30
AU2006246483A1 (en) 2006-12-21
ECSP045469A (es) 2005-01-28
IL165181A0 (en) 2005-12-18
CN100402026C (zh) 2008-07-16
AU2006246483B2 (en) 2010-06-24
CY1112800T1 (el) 2016-02-10
NO20045452L (no) 2005-03-01
EP1513519B1 (en) 2009-02-18
HK1074794A1 (en) 2005-11-25
US20050176806A1 (en) 2005-08-11
ES2321600T3 (es) 2009-06-09
NZ536832A (en) 2006-11-30
NO333585B1 (no) 2013-07-15

Similar Documents

Publication Publication Date Title
CN100402026C (zh) 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
CN100421659C (zh) 用于降低血浆脂蛋白(a)和心血管疾病危险因素的组合物和其制药用途
CN114159564A (zh) 包含etc1002及他汀类药物的固定剂量组合
US8834858B2 (en) Treatment for dyslipidemia
JP2005532338A5 (ja)
Basak et al. An overview on management of diabetic dyslipidemia
KR20010101790A (ko) (ｅ)-7-[4-(4-플루오로페닐)-6-이소프로필-2-[메틸(메틸술포닐)아미노]피리미딘-5-일](3ｒ,5ｓ)-3,5-디히드록시헵트-6-엔산 및 ｐ450 이소효소 3ａ4의 억제제, 유도제 또는기질을 함유하는 약물 조합물
AU2017224230A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
Gaw et al. Fibrates
US20170246133A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
Shimpi et al. Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
RU2806869C2 (ru) Применение мавоглуранта при снижении употребления алкоголя или при предупреждении рецидива употребления алкоголя
US20180250251A1 (en) Treatment of Patients with Familial Hypercholesterolemia on Lipid-Lowering Therapy
Husain et al. Research Journal of Medicine and Pharmacy
NZ548902A (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
JP2023536855A (ja) 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド
Rajput Lipid-modifying therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20081001